Clinical investigationsMetabolic syndrome and coronary angiographic disease progression: the Women’s Angiographic Vitamin & Estrogen trial☆
Section snippets
Study population and measures
A total of 423 postmenopausal women were randomized at 7 clinics between July 1997 and August 1999. Study participants were required to have at least 1 non-intervened coronary stenosis of 15% to 75% on baseline angiography. Follow-up angiograms were obtained on 320 women; 22 women died, and 8 women had non-fatal MI during the study. Because the primary outcome for the main trial included imputed scores for clinical events, these women were not required to have exit angiograms. Additionally, 13
Results
Women with (n = 177) and without (n = 117) the metabolic syndrome were of similar age, ethnic distribution, and educational level (Table II). Although the cohort’s mean LDL cholesterol level exceeded the NCEP III goal of <100 mg/dL, only 60% of the women were taking a statin at baseline, 2% were taking a fibrate, and <1% were taking niacin. Women with the metabolic syndrome were less likely to be assigned to take active vitamins (P = .02). As a group, the women were sedentary; 14% and 13% of
Discussion
Sixty percent of WAVE trial participants met the NCEP III definition of the metabolic syndrome, considerably higher than the 24% prevalence reported in the general population, and higher than the 43% prevalence reported for women 60 to 69 years old.3 In women with the metabolic syndrome, the annual reduction in minimum lumen diameter was twice that of women without the metabolic syndrome, although these rates were not statistically different, and new lesions were more frequently observed in
References (19)
- et al.
Obesity, mortality and cardiovascular disease in the Munster Heart Study (PROCAM)
Atherosclerosis
(1999) - et al.
Women’s Angiographic Vitamin & Estrogen trialdesign and methods
Control Clin Trials
(2002) - et al.
Development of new coronary atherosclerotic lesions during a 4-year multifactorial risk reduction programthe Stanford Coronary Risk Intervention Project (SCRIP)
J Am Coll Cardiol
(1994) - et al.
Comparison of the Heart and Estrogen/Progestin Replacement Study (HERS) cohort with women with coronary disease from the National Health and Nutrition Examination Survey III (NHANES III)
Am Heart J
(1998) - Third Report of the National Cholesterol Education (NCEP) Program Expert Panel on Detection, Evaluation and Treatment...
- et al.
Prevalence of the metabolic syndrome among US adultsfindings from the third National Health and Nutrition Examination Survey
JAMA
(2002) - et al.
Cardiovascular morbidity and mortality associated with the metabolic syndrome
Diabetes Care
(2001) - et al.
Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S
Circulation
(2001) - Resnick HE, Jones K, Ruotolo G, et al. Insulin resistance, the metabolic syndrome and risk of incident cardiovascular...
Cited by (36)
The metabolic syndrome and cardiovascular risk: A systematic review and meta-analysis
2010, Journal of the American College of CardiologyThe impact of metabolic syndrome and CRP on vascular phenotype in type 2 diabetes mellitus
2008, European Journal of Internal MedicineCitation Excerpt :MS is estimated to be present in 75–80% of DM2 patients and has been shown to influence cardiovascular risk [4,26] and fibrinolytic function [27,28]. In patients with MS but without diabetes, increased measures of atherosclerosis [14,29–31] and a higher incidence of cardiovascular events have been observed [27,32]. This has partly been attributed to impaired fibrinolytic function [27] due to altered regulation of PAI-1, tPA, and fibrinogen [28,33,34].
Metabolic Syndrome and Risk of Incident Cardiovascular Events and Death. A Systematic Review and Meta-Analysis of Longitudinal Studies
2007, Journal of the American College of CardiologyCitation Excerpt :Sample sizes ranged from 133 to 41,056 participants (total 172,537), and there was a wide range of prevalence of cardiovascular disease and diabetes mellitus at inception. The MetSyn was defined by WHO criteria in 6 studies (36,41,47,48,51,61), NCEP criteria in 12 studies (39,40,42,43,47,53–55,57,59,61,62), modified WHO criteria in 4 studies (28,39,54,58), and modified NCEP criteria in 10 studies (27,39,44–46,49,50,56,60). Most modifications substituted body mass index for waist circumference or waist-to-hip ratio, or omitted the proteinuria component of the WHO criteria.
- ☆
Supported by contracts (NO1-HV-68165, NO1-HV-68166, NO1-HV-68167, NO1-HV-68168, NO1-HV-68169, NO1-HV-68170) from the National Institutes of Health.